#calmodulinopathy #calcium-handling #long-qt-syndrome #CPVT #channelopathies

Calmodulinopathy

Definition

Calmodulinopathy is a rare, severe, predominantly de novo inherited cardiac channelopathy caused by heterozygous mutations in any of the three CALM genes (CALM1, CALM2, CALM3), all encoding identical calmodulin (CaM) protein. Despite heterozygosity (1 mutant allele per 6 encoding the same protein), penetrance is near-complete — explained by the dominance of mutant CaM within the pre-bound pool at cardiac ion channel targets. Clinical presentation is severe electrical instability in children and young adults, with high SCD risk. ClinGen classifies CALM1/2/3 as Definitive for LQTS and Moderate for CPVT (2026).

Key Concepts

CaM Structure and the Pre-Bound Pool

CaM: 149 amino acids, 17 kDa; 100% vertebrate sequence conservation; encoded by CALM1/2/3 — all producing identical protein (redundancy by design)
Two lobes (N and C), each with 2 EF-hand Ca²⁺ binding domains; C-lobe has 10× higher Ca²⁺ affinity and is the primary Ca²⁺-sensing lobe for channel modulation
At least 3 of 4 Ca²⁺ sites must be occupied ("holo-CaM") for downstream activation
In cardiomyocytes, 99% of CaM is pre-bound to cellular proteins; only ~50–100 nM is free — most CaM exists as pre-bound apo-CaM at diastolic Ca²⁺ levels
Pre-bound apo-CaM at channel IQ/preIQ motifs positions the C-lobe to sense local Ca²⁺ during channel opening — bulk cytosolic CaM diffusion is too slow for CDI kinetics
sources/calm-fcvm-2018, rating: high

Mechanism of High Penetrance

A 1:7 mutant:WT CaM ratio (heterozygous) is sufficient to impair CDI at Cav1.2 because mutant CaMs occupy the pre-bound pool equally with WT CaM — and even a minority of Ca²⁺-affinity-compromised CaMs prevent adequate C-lobe signalling during CDI
Targets requiring holo-CaM (e.g., CaMKII) are relatively spared — mutant CaM with reduced Ca²⁺ affinity forms fewer holo-CaM molecules, leaving WT holo-CaM to dominate
RyR2 inhibition by apo-CaM is Ca²⁺-independent → LQTS mutations spare RyR2 (Ca²⁺ affinity reduction does not disrupt apo-CaM–RyR2 binding); CPVT mutations disrupt RyR2 via a distinct conformational mechanism
sources/calm-fcvm-2018, rating: high

LQTS Phenotype — CDI Loss Mechanism

Core mechanism: Mutations reduce C-lobe Ca²⁺ affinity (EF III/IV residues) → pre-bound mutant CaM cannot sense Ca²⁺ at Cav1.2 cytoplasmic mouth → CDI abolished → ICaL gain of function → APD prolongation → QT prolongation → EADs → TdP/VF
Key mutations: CALM1-p.D130G (also CALM3), CALM2-p.D96V, CALM1-p.F142L, CALM2-p.D130V, CALM1-p.E141G, CALM2-p.D132H, CALM1-p.D132V
hiPSC-CM data (CALM1-p.F142L): CDI severely impaired; APD prolonged and non-rate-adaptive; Ca²⁺ transient amplitude increased but SR Ca²⁺ content normal; no spontaneous Ca²⁺ release events (RyR2 intact); IKs unaffected; CaMKII preserved/enhanced. Confirms CDI loss — not SR instability — as the sole arrhythmogenic mechanism in LQTS calmodulinopathy
IKs (Kv7.1) sparing: IKs modulation also requires C-lobe Ca²⁺ sensing — yet IKs appears unaffected in LQTS calmodulinopathy; PIP2-dependent IKs activation likely compensates for lost CaM–IKs signalling
Verapamil (ICaL blocker) shortens QT in CALM1-p.F142L hiPSC-CMs; selective sustained ICaL blockade (analogous to mexiletine for INaL in LQT3) is the theoretical ideal but not yet clinically available
sources/calm-fcvm-2018, rating: high; sources/arrhythmia-genetics-mgenetik-2025, rating: high

CPVT Phenotype — RyR2 Destabilisation Mechanism

Mutations: CALM1-p.N98S, CALM1-p.N54I, CALM3-p.A103V — smaller C-lobe Ca²⁺ affinity reduction vs. LQTS mutations; CDI relatively preserved
Mechanism: Mutant CaM alters the CaM–RyR2 3D binding interface → disrupts apo-CaM–dependent stabilisation of RyR2 closed state ("unzipping") → spontaneous diastolic Ca²⁺ waves → NCX-mediated transient inward current (ITI) → DADs → bidirectional VT
Mechanism elusive: CALM1-p.N98S shows inconsistent affinity changes (decreased vs. increased) across studies; CALM3-p.A103V strongly increases Ca²⁺ release events with normal RyR2 affinity → conformational binding interface changes (not affinity) are likely the true determinant
Treatment: Beta-blockers + flecainide/carvedilol by analogy to RYR2-CPVT; no calmodulinopathy-specific CPVT trial data as of 2018
sources/calm-fcvm-2018, rating: high

Mixed Phenotype and IVF

Some mutations (CALM2-p.D132E, CALM2-p.Q136P) produce combined QT prolongation + CPVT-type Ca²⁺ instability — likely impaired CDI with secondary SR instability when homeostatic compensation fails
CALM2-p.N98S (LQTS) vs. CALM1-p.N98S (CPVT) — identical protein product → same mutation can produce different phenotypes; modifier factors unknown, confirming calmodulinopathy is not gene-determined
CALM1-p.F90L → IVF only (mild QTc prolongation during exercise recovery only); impairs C-lobe conformational stability + CaM–RyR2 interface + SK channels
sources/calm-fcvm-2018, rating: high

ClinGen Gene-Disease Validity (2026)

CALM1/2/3 Definitive for LQTS (classified 09/25/2018)
CALM1/2/3 Moderate for CPVT — supported but not yet Definitive
Neonatal LQTS with QTc >600 ms without identifiable cause → CALM1/2/3 sequencing mandatory
sources/clingen-summary-2026-05-09, rating: high

Clinical Presentation and Management

Onset: infancy to early childhood; neonatal presentation with recurrent cardiac arrest possible; high SCD risk in the young
Extreme QTc (>600 ms) in LQTS phenotype; bidirectional VT in CPVT phenotype
Predominantly de novo mutations — negative family history does not exclude diagnosis. The International Calmodulinopathy Registry (74 patients) found the culprit variant de novo in 93% of screened families; the remainder had germline mosaicism in one parent, which carries recurrence risk for future pregnancies. (sources/inherited-arrhythmias-nrdp-2020, rating: very high)
One mutant allele out of six is sufficient. CALM1/2/3 sit on different chromosomes and share 85% nucleotide homology while encoding an identical 149-amino-acid protein, so heterozygosity still places a substantial mutant fraction in the pre-bound calmodulin pool — the structural reason penetrance is near-complete. (sources/inherited-arrhythmias-nrdp-2020)
LQTS management: Beta-blockers (non-selective); verapamil empirically; avoid QT-prolonging drugs; LCSD and ICD per standard LQTS escalation
CPVT management: Beta-blockers (non-selective) + flecainide; LCSD and ICD per standard CPVT protocol
No calmodulinopathy-specific treatment guidelines; management extrapolated from standard channelopathy algorithms
sources/calm-fcvm-2018, rating: high; sources/arrhythmia-genetics-mgenetik-2025, rating: high

Gene Therapy

Calmodulinopathies are unusually tractable for gene silencing, for one structural reason: all three CALM genes encode an identical 149-amino-acid protein while differing in nucleotide sequence. Knocking down one gene is therefore tolerable, and the redundancy that makes calmodulin essential also makes it selectively suppressible. (sources/gene-therapy-arrhythmia-cjca-2026, rating: high)

CRISPR interference against one promoter. A catalytically inactive Cas9 fused to a KRAB suppressor domain, with a gRNA targeting the CALM2 promoter, dramatically reduced CALM2 expression while preserving CALM1 and CALM3, and normalised action potentials and Ca²⁺/CaM-dependent L-type channel inactivation in hiPSC-CMs from a CALM2-p.D130G patient. (sources/gene-therapy-arrhythmia-cjca-2026)
A universal suppression-replacement construct. Three shRNAs knockdown all endogenous CALM genes while a shIMM CALM1 cDNA restores protein — normalising action potential duration in hiPSC-CMs carrying CALM1-p.F142L, CALM2-p.D130G and CALM3-p.D130G. This is the only genotype-universal strategy in inherited arrhythmia, covering a whole gene family with one therapeutic. (sources/gene-therapy-arrhythmia-cjca-2026; see concepts/SupRep-Therapy)
ASO knockdown — the most tunable option. A CALM1-selective ASO conjugated to palmitic acid normalised action potentials in CALM1-p.F142L hiPSC-CMs, and abolished caffeine/epinephrine-induced bidirectional VT in CALM1-p.Asn98Ser knock-in mice. It required >85% silencing of the mutant transcript, worked for up to 4 weeks, produced compensatory up-regulation of CALM2 and CALM3, and showed no toxicity despite >95% CALM1 silencing in skeletal muscle. (sources/gene-therapy-arrhythmia-cjca-2026)
Why ASO is attractive here specifically: it is re-dosable, avoids AAV immunogenicity, and — critically for a gene family where over-silencing could be lethal — its dose can be adjusted, unlike a single-shot viral construct.
All calmodulinopathy gene therapy is preclinical; no trial exists.

Contradictions / Open Questions

Same mutation → different phenotype (p.N98S across CALM1/2): CALM2-p.N98S reported as LQTS; CALM1-p.N98S as CPVT — identical protein product. Modifier genes, environmental factors, or ascertainment bias could all contribute, but mechanism is unknown. sources/calm-fcvm-2018
Mechanism of RyR2 destabilisation unresolved: CaM–RyR2 affinity changes are contradicted across labs; CALM3-p.A103V destabilises without affinity change. The nature of the 3D binding interface disruption has not been structurally characterised. sources/calm-fcvm-2018
IKs sparing by PIP2 — theoretical: PIP2-dependent IKs activation may compensate for lost CaM-mediated IKs enhancement in LQTS calmodulinopathy, but direct testing under PIP2 depletion conditions has not been reported. sources/calm-fcvm-2018
No clinical outcome data for any treatment (2018): Verapamil efficacy is hiPSC-CM–based only; no systematic clinical series for beta-blockers, ICaL blockers, or CPVT regimens in calmodulinopathy. sources/calm-fcvm-2018
Is suppressing one of three identical genes actually harmless over decades? The whole gene-therapy premise rests on calmodulin redundancy: CALM1, CALM2 and CALM3 encode the same protein, so silencing one should leave CaM levels adequate. But the compensation observed in mice (up-regulation of the other two genes) may be a young animal's response, and no study has followed long-term depletion of a single CALM gene, particularly outside the heart. The ASO evidence that silencing >95% of CALM1 in skeletal muscle left CaM protein unchanged is reassuring but short-term. (sources/gene-therapy-arrhythmia-cjca-2026, rating: high)
The universal construct assumes the mutant and wild-type alleles are silenced equally. Sup-Rep knocks down all three endogenous genes and replaces the protein wholesale, so it corrects the stoichiometry rather than removing the mutant. Whether that is sufficient when the mutant acts by a gain-of-function or dominant-negative mechanism at a specific binding interface — rather than by haploinsufficiency — has not been established for calmodulin. (sources/gene-therapy-arrhythmia-cjca-2026)

Connections

Related to entities/Long-QT-Syndrome
Related to entities/CPVT
Related to entities/RYR2
Related to entities/KCNQ1
Related to concepts/Cardiac-Action-Potential
Related to concepts/HCM-Calcium-Homeostasis
Related to concepts/iPSC-Derived-Cardiomyocytes
Related to concepts/Left-Cardiac-Sympathetic-Denervation
Related to concepts/ClinGen-Gene-Disease-Validity
Related to concepts/Sudden-Cardiac-Death
Related to concepts/Channelopathies
Related to concepts/SupRep-Therapy — the three-shRNA universal construct
Related to concepts/Gene-Silencing-Therapy — ASO knockdown of a single CALM gene